Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients

Neuropsychopharmacology

Volumn 39, Issue 13, 2014, Pages 3000-3008

  Düring, Signe ^a,b   Glenthøj, Birte Y ^a,b   Andersen, Gitte Saltoft ^a   Oranje, Bob ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CANNABIS; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OPIATE; OXAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG POTENCY; FEMALE; HABITUATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONOTHERAPY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOPHYSIOLOGY; PSYCHOSIS; RISK REDUCTION; SCHIZOPHRENIA; SENSITIZATION; SENSORY GATING; SENSORY SYSTEM; SOMATOSENSORY DISORDER; STARTLE REFLEX; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; AUDITORY STIMULATION; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EVOKED AUDITORY RESPONSE; GAIT DISORDERS, NEUROLOGIC; ITALY; PSYCHOLOGICAL RATING SCALE; PSYCHOPHYSICS; STATISTICS; YOUNG ADULT;

ACOUSTIC STIMULATION; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DOPAMINE ANTAGONISTS; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; PREPULSE INHIBITION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOPHYSICS; SCHIZOPHRENIA; STATISTICS AS TOPIC; SULPIRIDE; YOUNG ADULT;

EID: 84936095415     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.152     Document Type: Article

References (44)

1. Aasen I, Kolli L, Kumari V (2005). Sex effects in prepulse inhibition and facilitation of the acoustic startle response: implications for pharmacological and treatment studies. J Psychopharmacol 19: 39-45.
2. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009). Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205: 119-128.
3. Aggernaes B, Glenthoj BY, Ebdrup BH, Rasmussen H, Lublin H, Oranje B (2010). Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine. Int J Neuropsychopharmacol 13: 1383-1395.
4. Arnfred SM, Chen AC, Glenthoj BY, Hemmingsen RP (2003). Normal p50 gating in unmedicated schizophrenia outpatients. Am J Psychiatry 160: 2236-2238.
5. Boutros NN, Zouridakis G, Overall J (1991). Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 22: 40-45.
6. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343.
7. Braff DL, Geyer MA, Swerdlow NR (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258.
8. Braff DL, Light GA, Swerdlow NR (2007). Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry 61: 1204-1207.
9. Cadenhead KS, Geyer MA, Butler RW, Perry W, Sprock J, Braff DL (1997). Information processing deficits of schizophrenia patients: relationship to clinical ratings, gender and medication status. Schizophr Res 28: 51-62.
10. Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX (2008). Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 33: 497-512.
11. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH (2007). Failure to find P50 suppression deficits in young firstepisode patients with schizophrenia and clinically unaffected siblings. Schizophr Bull 33: 1319-1323.
12. Duncan E, Szilagyi S, Schwartz M, Kunzova A, Negi S, Efferen T et al (2003). Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol. Psychiatry Res 120: 1-12.
13. Hetrick WP, Sandman CA, Bunney WE Jr, Jin Y, Potkin SG, White MH (1996). Gender differences in gating of the auditory evoked potential in normal subjects. Biol Psychiatry 39: 51-58.
14. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P et al (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20: 389-409.
15. Jensen KS, Oranje B, Wienberg M, Glenthoj BY (2007). The effects of increased central serotonergic activity on prepulse inhibition and habituation of the human startle response. Neuropsychopharmacology 32: 2117-2124.
16. Jensen KS, Oranje B, Wienberg M, Glenthoj BY (2008). The effects of increased serotonergic activity on human sensory gating and its neural generators. Psychopharmacology (Berl) 196: 631-641.
17. Kay SR, Opler LA, Lindenmayer JP (1988). Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23: 99-110.
18. Kumari V (2011). Sex differences and hormonal influences in human sensorimotor gating: implications for schizophrenia. Curr Top Behav Neurosci 8: 141-154.
19. Kumari V, Aasen I, Sharma T (2004). Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophr Res 69: 219-235.
20. Kumari V, Fannon D, Sumich AL, Sharma T (2007). Startle gating in antipsychotic-naive first episode schizophrenia patients: one ear is better than two. Psychiatry Res 151: 21-28.
21. Kumari V, Sharma T (2002). Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology (Berl) 162: 97-101.
22. Kumari V, Soni W, Sharma T (2002). Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics. Schizophr Res 55: 139-146.
23. Ludewig K, Geyer MA, Vollenweider FX (2003). Deficits in prepulse inhibition and habituation in never-medicated, firstepisode schizophrenia. Biol Psychiatry 54: 121-128.
24. Mackeprang T, Kristiansen KT, Glenthoj BY (2002). Effects of antipsychotics on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry 52: 863-873.
25. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2008). Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 105: 224-235.
26. Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H et al (2012a). Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 69: 1195-1204.
27. Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S et al (2012b). Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol Psychiatry 71: 898-905.
28. Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthoj BY (2013). P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull 39: 472-480.
29. Oranje B, Geyer MA, Bocker KB, Leon KJ, Verbaten MN (2006). Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res 143: 147-158.
30. Oranje B, Glenthoj BY (2013). Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication. Schizophr Bull. 39: 684-691.
31. Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN (1999). P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Biol Psychiatry 45: 883-890.
32. Oranje B, Van Oel CJ, Gispen-de Wied CC, Verbaten MN, Kahn RS (2002). Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J Clin Psychopharmacol 22: 359-365.
33. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997). Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280: 73-82.
34. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff DL (2002). Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry 159: 1375-1381.
35. Quednow BB, Frommann I, Berning J, Kuhn KU, Maier W, Wagner M (2008). Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biol Psychiatry 64: 766-773.
36. Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier Wet al (2006). Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biol Psychiatry 59: 536-545.
37. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280: 83-97.
38. Schwarzkopf SB, Lamberti JS, Smith DA (1993). Concurrent assessment of acoustic startle and auditory P50 evoked potential measures of sensory inhibition. Biol Psychiatry 33: 815-828.
39. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ et al (2007). Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res 92: 237-251.
40. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007). Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33: 69-94.
41. Volter C, Riedel M, Wostmann N, Aichert DS, Lobo S, Costa A et al (2012). Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach. Int J Neuropsychopharmacol 15: 1427-1440.
42. Wienberg M, Glenthoj BY, Jensen KS, Oranje B (2010). A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers. J Psychopharmacol 24: 1183-1192.
43. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R et al (1990). SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47: 589-593.
44. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C et al (2007). Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95: 134-142.